<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672280</url>
  </required_header>
  <id_info>
    <org_study_id>UCMSC-3</org_study_id>
    <nct_id>NCT02672280</nct_id>
  </id_info>
  <brief_title>Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects</brief_title>
  <acronym>SEESCMMSCTSD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>South China Research Center for Stem Cell and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South China Research Center for Stem Cell and Regenerative Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the safety and exploratory efficacy of the
      medical collagen membrane with umbilical cord derived mesenchymal stem cells in the treatment
      of patients with skin defects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events that are related to study treatment and associated with the grafting site</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of wound closure as determined</measure>
    <time_frame>Up to Month 3 after the last grafting day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar outcome assessment</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of contracture release or revision surgeries</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of increased temperature sensitivity</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of paresthesias, pain, dulling of sensation assessed</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of infections at grafting sites</measure>
    <time_frame>Up to Month 6 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all adverse events</measure>
    <time_frame>Up to Month 36 after the last grafting day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage area of re-grafting as determined</measure>
    <time_frame>Up to Month 6 after the last grafting day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wounds</condition>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Medical Collagen Membrane with MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Collagen Membrane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of medical collagen membrane only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical Collagen Membrane with MSC</intervention_name>
    <arm_group_label>Medical Collagen Membrane with MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical Collagen Membrane</intervention_name>
    <arm_group_label>Medical Collagen Membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 70, borh gender.

          -  Patient able and willing to sign informed consent and comply with study procedures.

          -  Women of childbearing potential must use birth control pills, barriers or abstinence
             and have a negative pregnancy test.

          -  Deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound
             coverage due to: burn injury, diabetic foot ulcer or wounds caused by mechanical
             damage or iatrogenic injury.

        Exclusion Criteria:

          -  Patient refusal.

          -  Patient has a documented history of allergy or sensitivity to any of the animal
             products used in preparation of skin substitute. These products include bovine blood,
             bovine collagen, and bovine collagenase.

          -  Patient has a documented history of allergy or sensitivity to any of the
             antimicrobials or reagents used in preparation and application of skin substitute
             including the irrigation solution used before and after grafting.

          -  Patient has a current diagnosis of an invasive burn wound infection in unexcised burn
             wound.

          -  Patient has tunnels or sinus tracts that cannot be completely debrided.

          -  Serious primary diseases of the liver, kidney and hematopoietic system, Abnormal liver
             function(glutamic-pyruvic transaminase(ALT), glutamicoxalacetic transaminase (AST) is
             2 times higher than the normal value), creatinine(Cr) is higher than the upper limit
             of the normal value.

          -  Other clinical trial participants within 3 months.

          -  A random blood sugar reading &gt;/=450 mg/dL.

          -  Investigators judge other conditions not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuetao Pei, M.D., Ph.D</last_name>
    <phone>0086-10-68164807</phone>
    <email>peixuetao@scrm.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bowen Zhang, Ph.D</last_name>
    <phone>0086-10-66931947</phone>
    <email>zhangbowen@scrm.org.cn</email>
  </overall_contact_backup>
  <link>
    <url>http://link.springer.com/article/10.1007%2Fs11427-007-0069-2</url>
  </link>
  <reference>
    <citation>He L, Nan X, Wang Y, Guan L, Bai C, Shi S, Yuan H, Chen L, Liu D, Pei X. Full-thickness tissue engineered skin constructed with autogenic bone marrow mesenchymal stem cells. Sci China C Life Sci. 2007 Aug;50(4):429-37.</citation>
    <PMID>17653662</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2016</study_first_submitted>
  <study_first_submitted_qc>January 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>January 31, 2016</last_update_submitted>
  <last_update_submitted_qc>January 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

